Natalie Byrne

M18 Shifting COPD and asthma care left: analysis of the ‘one stop’ community diagnostic clinic in the West of Ireland

Chul-Hwa Song, Natalie Byrne, Niall Duignan, Erin Hall et autres

Introduction In Ireland, the Sláintecare programme has identified chronic disease as a priority, aiming to transition asthma and chronic obstructive pulmonary disease (COPD) care from tertiary care to patient-centred primary care and community hubs. This includes community-based resources: GP-direct access spirometry, community …

ie (code pays fourni par la source)

120MO Inupadenant combined with chemotherapy in patients with non-squamous NSCLC progressing on or after immune checkpoint inhibitor therapy: Results from dose-finding part of the A2A-005 trial

Kristof Cuppens, G. Lo Russo, Óscar Juan, E. Felip et autres

Immunosuppressive adenosine accumulates at high levels in advanced non-small cell lung cancer (NSCLC), where treatment options remain limited following immune checkpoint inhibitor (ICI) therapy. Inupadenant, a selective adenosine-2A receptor (A2AR) inhibitor, counteracts the adenosine immunosuppressive effects. Combining inupadenant with standard chemotherapy may …

be, it, es, us, ca, fr, ch (code pays fourni par la source)

Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial

Frances Hall, Joseph Cheriyan, Andrew P. Cope, James Galloway et autres

BACKGROUND: From early in the COVID-19 pandemic, evidence suggested a role for cytokine dysregulation and complement activation in severe disease. In the TACTIC-R trial, we evaluated the efficacy and safety of baricitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2, and …

gb (code pays fourni par la source)

Supplementary Table 2 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Jonathan R. Dry, Sandra Pavey, Christine A. Pratilas, Chris Harbron et autres

Supplementary Table 2 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Supplementary Figure 5 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Jonathan R. Dry, Sandra Pavey, Christine A. Pratilas, Chris Harbron et autres

Supplementary Figure 5 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Supplementary Figure 7 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Jonathan R. Dry, Sandra Pavey, Christine A. Pratilas, Chris Harbron et autres

Supplementary Figure 7 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Supplementary Figures 8-12 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Jonathan R. Dry, Sandra Pavey, Christine A. Pratilas, Chris Harbron et autres

Supplementary Figures 8-12 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Supplementary Table 1 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Jonathan R. Dry, Sandra Pavey, Christine A. Pratilas, Chris Harbron et autres

Supplementary Table 1 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Supplementary Table 5 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Jonathan R. Dry, Sandra Pavey, Christine A. Pratilas, Chris Harbron et autres

Supplementary Table 5 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Supplementary Table 7 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Jonathan R. Dry, Sandra Pavey, Christine A. Pratilas, Chris Harbron et autres

Supplementary Table 7 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Supplementary Table 3 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Jonathan R. Dry, Sandra Pavey, Christine A. Pratilas, Chris Harbron et autres

Supplementary Table 3 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Supplementary Table 6 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Jonathan R. Dry, Sandra Pavey, Christine A. Pratilas, Chris Harbron et autres

Supplementary Table 6 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)